Recursion Pharmaceuticals Inc - Ordinary Shares - Class A
RXRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.59B
Close$
Share Statistics
| Market cap | $1.59 Billion |
|---|---|
| Enterprise Value | $1.04 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.44 |
| Beta | 1 |
| Outstanding Shares | 529,303,984 |
Return
| Return on Equity | -54.62% |
|---|---|
| Return on Assets | -41.79% |
| Return on Invested Capital | -49.59% |
Valuation & Multiples
| P/E Ratio | -2.97 |
|---|---|
| PEG | 7.07 |
| Price to Sales | - |
| Price to Book Ratio | 3.34 |
| Enterprise Value to Revenue | 15.73 |
| Enterprise Value to EBIT | -1.74 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$17.46 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$10.97 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 64.16% |
|---|---|
| Total Calls | 298▼ 99.99% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.09%▼ 75.04% |
|---|---|
| Total Invested | $1.79M▼ 99.83% |
| Investors Holding | 12▼ 338.00% |
ESG Score
No data
About Recursion Pharmaceuticals Inc
218 employeesRecursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patient...